Dulaglutide Reduces CV Events, Renal Progression in Type 2 Diabetes
In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years.
Diabetes
Ertugliflozin Linked to Better Renal Function in Type 2 Diabetes
Ertugliflozin may be protective of renal function in patients with type 2 diabetes.
No Evidence of Legacy Effect Seen for Intensive Glucose Lowering
Findings based on 15-year follow-up study conducted among veterans with type 2 diabetes
Hip Fracture Linked to Increased Risk for Death in T2DM Patients
Correlation not affected by adjustment for cardiovascular disease, end-stage renal disease
Poor Glycemic Control Linked to Sarcopenia in T2DM
Correlation independent of major covariates including anthropometric factors and diabetes duration
Worse Glycemic Control in Diabetics Predicts Adverse Cancer Outcomes After Prostatectomy
In a study, men with a higher preoperative hemoglobin A1c level had greater risks for developing castration-resistant prostate cancer and metastasis.
Fournier Gangrene Is Safety Concern With SGLT2 Inhibitors
FDA identified 55 cases of FG in patients on SGLT2 inhibitors from March 2013 through January 2019
Nearly Half of Type 2 Diabetics Have Undiagnosed CKD
Undiagnosed chronic kidney disease is present in 49% of patients with type 2 diabetes mellitus in the United States, a study found.
Dementia Predicts CKD Progression, Death in Type 2 Diabetes
In type 2 diabetes patients, a dementia diagnosis preceded vascular events such as kidney disease progression by a mean 2998 days or roughly 8 years.
Intensive Blood Pressure Therapy Aids Patients With T2DM
Overall death from any cause reduced, regardless of cardiovascular risk
Next post in Diabetes
